Described are devices and methods for use in connection with organ replacement or organ assist therapy in a patient.

Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Feeder cell products are needed to enhance growth of cells that are being cultured. The current process produces feeder cells by selecting a source for blood material containing mononuclear cells (MNCs) and other blood components, combining blood material from a plurality of donors, isolating the MNCs from the other blood components so as to form isolated heterogenous MNCs. Afterwards, the isolated heterogeneous MNCs is irradiated to produce the feeder cells.

This disclosure relates to methods of preserving mesenchymal stromal/stem cells (MSCs) for use in clinical applications. In certain embodiments, this disclosure relates to methods of preserving MSCs comprising mixing MSCs with interferon-gamma prior to cryopreserving, freezing, or cooling the MSCs to a temperature below zero degrees Celsius.

A biological sheet storage device includes a fixation arrangement and a storage box. The fixation arrangement includes a first carrier, a second carrier and a fixing piece. The first carrier is configured to carry a biological sheet and positioned on the second carrier. The fixing piece is configured to fix the first carrier on the second carrier. The storage box is configured to encapsulate the fixation arrangement carrying the biological sheet. A limiting mechanism for limiting the fixation arrangement is included in the storage box.

Methods of treating an ischemic disease in a subject are provided. Accordingly there is provided a method comprising administering to the subject a therapeutically effective amount of cells with reduced level of expression and/or activity of TNFR1, thereby treating the ischemic disease in the subject. Also provided is a method comprising treating with TNFalpha cells with reduced expression and/or activity of TNFR1 and administering to the subject a therapeutically effective amount of said cells, thereby treating the ischemic disease in the subject.

Disclosed is a device for supporting and connecting an excised organ (such as a heart, a pair of lungs, a kidney, or a liver) during ex vivo perfusion. The device includes a resilient and flexible sheet having a first portion for contacting and supporting the organ thereon, and a second portion comprising an opening for forming a connection between the organ and a conduit to allow fluid communication between the conduit and the organ. The device also includes a magnetic material embedded in the second portion of the sheet for magnetically securing the connection between the conduit and the organ.

Compositions for and methods of manufacturing a fucosylated cell population are provided. The method may include expansion of the cells and/or cryopreservation of the cells under conditions that retain optimum levels of cell surface fucosylation.

The invention relates to a method of preservation of nucleic acid sequences in histological tissues which comprises: treating a concentrated formaldehyde solution in water with basic ion-exchange resins; diluting the resulting acid-deprived formaldehyde solution with phosphate buffer pH 7.2-7.4 up to a concentration ranging between 2 and 4%; contacting the resulting acid-deprived formaldehyde solution obtained with the tissue samples; optionally embedding the samples fixed in paraffin.

Relates to a method for pathogen reduction of a blood product comprising: i) removing oxygen from a blood product; ii) reducing blood pathogens from said blood product t: adding amustaline (S-303) to a final concentration of 0.2 millimolar (mM); and glutathione (GSH) to a concentration of 20 mM; iii) reducing S-303 to a concentration of less than 1 nmol/L comprising incubating said oxygen reduced blood product under oxygen reduced conditions for up to 6 hours; and further relates to a pathogen reduced, oxygen reduced blood product having an oxygen saturation (sO.sub.2) of less than 25%, a pCO.sub.2 of 90 mmHg or less at 37° C., and having a amustaline (S-303) concentration of less than 1 nmol/L.